Clinical Trials
248 trialsNCT04704934 2026-05-27
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Daiichi Sankyo
Phase 3 Active not recruiting
NCT05052801 2026-05-27
FORTITUDE-101
Amgen
Phase 3 Completed
NCT06346392 2026-05-27
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Active not recruiting
NCT07431281 2026-05-27
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT06768164 2026-05-20
BYQoL-GC
Assistance Publique - Hôpitaux de Paris
Phase 3 Recruiting
NCT05152147 2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT07488611 2026-05-19
PROGAIN
Soonchunhyang University Hospital
Phase 3 Recruiting
NCT05568095 2026-05-08
STAR-221
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT03504397 2026-05-04
Spotlight
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT06346197 2026-04-21
CIME
Centre Leon Berard
Phase 3 Recruiting
NCT07217704 2026-04-20
FAPI-GO
SOFIE
Phase 3 Recruiting
NCT03653507 2026-04-17
GLOW
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT07518147 2026-04-08
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06731478 2026-03-16
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
Phase 3 Recruiting
NCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04882241 2026-03-06
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05871099 2026-03-06
Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not
The Affiliated Hospital of Qingdao University
Phase 3 Recruiting
NCT03675737 2026-02-27
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06532006 2026-02-27
A Phase â…¢ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shanghai Henlius Biotech
Phase 3 Recruiting
NCT07437573 2026-02-27
KLASS-09
Korea University Guro Hospital
Phase 3 Completed
NCT04871412 2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3 Recruiting
NCT03399110 2026-01-27
XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
Fudan University
Phase 3 Active not recruiting
NCT07366528 2026-01-26
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Ruijin Hospital
Phase 3 Recruiting
NCT07315750 2026-01-21
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT04342910 2026-01-20
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT07331454 2026-01-12
Robotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Not yet recruiting
NCT07314203 2026-01-02
SOP-XH-IRB
Fujian Medical University
Phase 3 Not yet recruiting
NCT07304271 2025-12-26
IPa-Gastric
Karolinska University Hospital
Phase 3 Recruiting
NCT03042169 2025-12-23
SURGIGAST
University Hospital, Lille
Phase 3 Terminated
NCT06093425 2025-12-17
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 3 Not yet recruiting
NCT05111626 2025-12-15
FORTITUDE-102
Amgen
Phase 3 Active not recruiting
NCT03615326 2025-12-11
MK-3475-811
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT03013010 2025-12-08
PREACT
Shanghai Cancer Hospital, China
Phase 3 Completed
NCT03813784 2025-09-16
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT02872116 2025-08-07
CheckMate649
Bristol-Myers Squibb
Phase 3 Completed
NCT06793917 2025-07-20
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Fujian Cancer Hospital
Phase 3 Recruiting
NCT03348150 2025-07-17
PERISCOPEII
The Netherlands Cancer Institute
Phase 3 Active not recruiting
NCT06949033 2025-07-10
Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Lanzhou University Second Hospital
Phase 3 Recruiting
NCT01815853 2025-07-03
Neo-CRAG
Sun Yat-sen University
Phase 3 Completed
NCT06939439 2025-07-01
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Active not recruiting
NCT04032119 2025-05-04
RCT of Gastric ESD With or Without Epineprhine Added Solution
Chinese University of Hong Kong
Phase 3 Completed
NCT06944496 2025-04-25
A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.
Phase 3 Not yet recruiting
NCT06925243 2025-04-22
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Lanzhou University Second Hospital
Phase 3 Recruiting
NCT05593458 2025-04-09
TACTIC
Zhejiang University
Phase 3 Recruiting
NCT06755554 2025-03-30
ICGastr
Ukrainian Society of Clinical Oncology
Phase 3 Recruiting
NCT02349412 2025-02-07
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02112214 2024-12-27
HELPER
National Cancer Center, Korea
Phase 3 Active not recruiting
NCT04214990 2024-12-27
EASTERN
National Cancer Center, Korea
Phase 3 Recruiting
NCT02867839 2024-12-03
RESCUE-GC
Peking University Cancer Hospital & Institute
Phase 3 Terminated